K-Pio-Gm 1mg Tablet ER is an extended-release oral antidiabetic medication combining Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The extended-release formulation allows for once-daily dosing, promoting better patient compliance and stable plasma drug concentrations. K-Pio-Gm 1mg Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. This combination therapy addresses multiple pathophysiological defects of type 2 diabetes, offering a comprehensive approach to glycemic management.